TY - JOUR T1 - Hemodynamic Differences Between Women and Men with Elevated Blood Pressure in China JF - medRxiv DO - 10.1101/2021.03.22.21253998 SP - 2021.03.22.21253998 AU - César Caraballo AU - Shiwani Mahajan AU - Jianlei Gu AU - Yuan Lu AU - Erica S. Spatz AU - Rachel P. Dreyer AU - MaoZhen Zhang AU - NingLing Sun AU - Yihong Ren AU - Xin Zheng AU - Hongyu Zhao AU - Hui Lu AU - Zheng J. Ma AU - Harlan M. Krumholz Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/26/2021.03.22.21253998.abstract N2 - Background Whether there are sex differences in hemodynamic profiles among people with elevated blood pressure is not well understood and could guide personalization of treatment.Methods and results We described the clinical and hemodynamic characteristics of adults with elevated blood pressure in China using impedance cardiography. We included 45,082 individuals with elevated blood pressure (defined as systolic blood pressure of ≥130 mmHg or a diastolic blood pressure of ≥80 mmHg), of which 35.2% were women. Overall, women had a higher mean systolic blood pressure than men (139.0 [±15.7] mmHg vs 136.8 [±13.8] mmHg, P<0.001), but a lower mean diastolic blood pressure (82.6 [±9.0] mmHg vs 85.6 [±8.9] mmHg, P<0.001). After adjusting for age, region, and body mass index, women <50 years old had lower systemic vascular resistance index (beta-coefficient [β] -31.68; 95% CI: -51.18, -12.19) and higher cardiac index (β 0.07; 95% CI: 0.04, 0.09) than men of their same age group, whereas among those ≥50 years old women had higher systemic vascular resistance index (β 120.43; 95% CI: 102.36, 138.51) but lower cardiac index (β -0.15; 95% CI: -0.16, -0.13). Results were consistent with a propensity score matching sensitivity analysis, although the magnitude of the SVRI difference was lower and non-significant. However, there was substantial overlap between women and men in the distribution plots of these variables, with overlapping areas ranging from 78% to 88%.Conclusions Our findings indicate that there are sex differences in hypertension phenotype, but that sex alone is insufficient to infer an individual’s profile.Subject Terms Hemodynamics; Women, Sex, and Gender; High Blood Pressure; Hypertension; EpidemiologyCompeting Interest StatementDISCLOSURES Yuan Lu is supported by the National Heart, Lung, and Blood Institute (K12HL138037) and the Yale Center for Implementation Science. She was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion. Erica S. Spatz receives support from the Food and Drug Administration to support projects within the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI); the National Institute on Minority Health and Health Disparities (U54MD010711-01) to study precision-based approaches to diagnosing and preventing hypertension; and the National Institute of Biomedical Imaging and Bioengineering (R01EB028106-01) to study a cuff-less blood pressure device. Xin Zheng is supported by the CAMS Innovation Fund for Medical Science (2016-I2M-1-006), the National Key Research and Development Program (2016YFE0103800) from the Ministry of Science and Technology of China. Hui Lu is supported by the National Key R&D Program of China (2018YFC0910500) and Neil Shen's SJTU Medical Research Fund. Zheng J. Ma is affiliated with Beijing Li-Heng Medical Technologies, Ltd, which designed the ICG device used in this study. Harlan Krumholz works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs; was a recipient of a research grant, through Yale, from Medtronic and the U.S. Food and Drug Administration to develop methods for post-market surveillance of medical devices; was a recipient of a research grant with Medtronic and is the recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Ben C. Martin Law Firm for work related to the Cook IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the founder of HugoHealth, a personal health information platform, and co-founder of Refactor Health, an enterprise healthcare AI-augmented data management company. The other co-authors report no potential competing interests.Funding StatementThis study was self-funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project received an exemption for review from the Institutional Review Board at Yale School of Medicine and at Shanghai Jiao Tong University College of Biotechnology, as we used de-identified data provided by the iKang group.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from author ZJ Ma upon reasonable request from qualified researchers. ER -